Boehringer Ingelheim USA Corporation

QUANTRO Therapeutics achieved a milestone with Boehringer Ingelheim in developing first-in-class cancer treatments, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, aiming to transform cancer treatment options.

QUANTRO Therapeutics achieved a milestone in its joint R&D with Boehringer Ingelheim, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, advancing first-in-class cancer treatments. The collaboration aims to address unmet cancer treatment needs, with potential transaction value exceeding EUR 500 million.

QUANTRO Therapeutics announced a key milestone in its joint R&D program with Boehringer Ingelheim, successfully applying QUANTROseq® technology to achieve technical proof-of-concept and identify high-quality hits for an undruggable transcription factor, aiming to develop first-in-class cancer treatments. The collaboration could exceed EUR 500 million in value.

QUANTRO Therapeutics achieved a milestone in its joint R&D with Boehringer Ingelheim, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, advancing towards first-in-class cancer treatments. The collaboration aims to address unmet needs in cancer therapy, with potential transaction values exceeding EUR 500 million.

QUANTRO Therapeutics and Boehringer Ingelheim achieved a key R&D milestone, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, advancing first-in-class cancer treatments. QUANTRO will receive milestone payments, with potential transaction value exceeding EUR 500 million.

American Clinical Research Services acquires Elixia; Oxford BioDynamics collaborates with King's College London post APIPPRA trial; Recursion's BioHive-2 ranks 35 on TOP500 supercomputers list; OM1 launches three AI-powered products; Oracle enhances Clinical One RTSM; Boehringer Ingelheim adopts ArisGlobal's LifeSphere Clarity; OGT introduces SureSeq Myeloid Fusion Panel; Lindus Health debuts All-in-One Diagnostics CRO; CuriMeta and NashBio form data licensing agreement.

Four investors invest $400M in Hercules CM NewCo, licensing weight loss drugs from Jiangsu Hengrui. The startup could pay Hengrui up to $5.7B based on milestones. Its lead drug, HRS-7535, targets Type 2 diabetes and obesity, with two others in development. Bain Capital holds a 39% stake.

GSK removed branded Flovent, a crucial asthma drug for children, from the US market, replacing it with a costly generic lacking insurance coverage. This has left families struggling to afford essential asthma medications, despite some manufacturers capping out-of-pocket costs at $35. The situation endangers children's health, with limited, expensive alternatives available.

Boehringer Ingelheim aims to launch 25 new treatments by 2030, focusing on oncology, mental health, and cardiovascular diseases. It plans 10 new Phase II and III trials soon, with promising candidates like Brigimadlin and zongertinib. Despite slow sales of Cyltezo, 2023 saw a 9.7% sales increase, driven by Jardiance and Ofev.

At SCOPE, experts emphasized integrating clinical research into healthcare, advocating for collaboration, innovation, and patient-first approaches. Key strategies include reducing costs, decentralizing trials, and leveraging technology for a seamless care-research continuum. The goal is to make trials less burdensome, more inclusive, and a routine part of healthcare, ensuring benefits reach a diverse patient population.